Evolución del consumo de fármacos antipsicóticos en Castilla y León (1990-2001)
| dc.contributor.author | Javier García del Pozo | |
| dc.contributor.author | Laura Isusi Lomas | |
| dc.contributor.author | Alfonso Carvajal García‐Pando | |
| dc.contributor.author | Igor Martín Rodríguez | |
| dc.contributor.author | María Sáinz-Gil | |
| dc.contributor.author | Victorina García del Pozo | |
| dc.contributor.author | Alfonso Velasco Martín | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T14:50:18Z | |
| dc.date.available | 2026-03-22T14:50:18Z | |
| dc.date.issued | 2003 | |
| dc.description | Citaciones: 10 | |
| dc.description.abstract | The consumption of antipsychotic drugs in Castile and Leon grew by 146% throughout the twelve months studied. The marketing of new atypical antipsychotic drugs and the legal measures related to the deinstitutionalization of mental patients may have played a major role in this increase. The marketing of the new antipsychotic drugs has led to a change in their pattern of use and has give rise to an rise in the direct costs. The consumption of these medications not charged to the National Health System is minor, but not negligible. | |
| dc.identifier.doi | 10.1590/s1135-57272003000600006 | |
| dc.identifier.uri | https://doi.org/10.1590/s1135-57272003000600006 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/48841 | |
| dc.language.iso | es | |
| dc.publisher | Ministry of Health of Spain | |
| dc.relation.ispartof | Revista Española de Salud Pública | |
| dc.source | Instituto Nacional de Salud | |
| dc.subject | Antipsychotic | |
| dc.subject | Consumption (sociology) | |
| dc.subject | Christian ministry | |
| dc.subject | Medicine | |
| dc.subject | Haloperidol | |
| dc.subject | Defined daily dose | |
| dc.subject | Risperidone | |
| dc.subject | Psychiatry | |
| dc.subject | Drug | |
| dc.title | Evolución del consumo de fármacos antipsicóticos en Castilla y León (1990-2001) | |
| dc.type | article |